A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: PF-04856883
- Registration Number
- NCT01637285
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of the study is to further evaluate the PK characteristics of PF-04856883.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 49
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-04856883 Treatment Arm 4 PF-04856883 - PF-04856883 Treatment Arm 2 PF-04856883 - PF-04856883 Treatment Arm 3 PF-04856883 - PF-04856883 Treatment Arm 1 PF-04856883 -
- Primary Outcome Measures
Name Time Method PF-04856883 Pharmacokinetics including Cmax, Tmax, AUCo-infinity, AUClast, Cl/F, Vz/F and t1/2 4 weeks
- Secondary Outcome Measures
Name Time Method Number of subjects with abnormal clinical laboratory results 4 weeks Number of subjects with abnormal ECGs 4 weeks Number of subjects with abnormal vital signs 4 weeks Number of subjects with AEs reported 4 weeks Number of subjects with abnormal physical examination findings 4 weeks
Trial Locations
- Locations (1)
New Haven Clinical Research Unit
🇺🇸New Haven, Connecticut, United States